RAPH1

Across TCGA pan-cancer cohorts, RAPH1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAPH1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAPH1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAPH1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where RAPH1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.331	0.484	.019	13	view →
UCEC	OS	Quartile	All	1.000	0.854	.028	4	view →
CCRCC	DFS	Quartile	III,IV	0.876	0.459	.033	3	view →
LUAD	DFS	Tertile	II,III,IV	0.344	0.716	.031	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.895	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAPH1–PDAC (DFS)

Open the PDAC breakdown →